Infections in steroid-refractory chronic graft versus host disease patients treated with ruxolitinib, ibrutinib, or belumosudil
- 31 July 2025
- journal article
- other
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1410-1412
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Axatilimab: First ApprovalDrugs, 2024
- FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic TherapyThe Oncologist, 2022
- FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyClinical Cancer Research, 2022
- Updates in chronic graft-versus-host diseaseHematology-American Society Hematology Education Program, 2021
- Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar StudyBlood, 2021
- Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD ConsortiumBlood Advances, 2021
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 2021
- Ibrutinib for chronic graft-versus-host disease after failure of prior therapyBlood, 2017
- Treatment and management of graft-versus-host disease: improving response and survivalTherapeutic Advances in Hematology, 2013
- Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host DiseaseTransplantation and Cellular Therapy, 2008